David Yestin Lewis

David Yestin Lewis

Auto-generated profile, based on publicly available information

David Yestin Lewis

Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
AIAgnese Irkle
Agnese Irkle
AVAlex T. Vesey
Alex T. Vesey
DLDavid Y. Lewis
David Y. Lewis
JSJeremy N. Skepper
Jeremy N. Skepper
JBJoseph L. E. Bird
Joseph L. E. Bird
ADAnthony P. Davenport
Anthony P. Davenport
Vascular calcification is a complex biological process that is a hallmark of atherosclerosis. While macrocalcification confers plaque stability, microcalcification is a key feature of high-risk atheroma and is associated with increased morbidity and mortality. Positron emission tomography and X-ray computed tomography (PET/CT) imaging of atherosclerosis using 18F-sodium fluoride (18F-NaF) has the potential to identify pathologically high-risk nascent microcalcification. However, the precise molecular mechanism of 18F-NaF vascular uptake is still unknown. Here we use electron microscopy, autoradiography, histology and preclinical and clinical PET/CT to analyse 18F-NaF binding. We show that 18F-NaF adsorbs to calcified deposits within plaque with high affinity and is selective and specific. 18F-NaF PET/CT imaging can distinguish between areas of macro- and microcalcification. This is the only currently available clinical imaging platform that can non-invasively detect microcalcification in active unstable atherosclerosis. The use of 18F-NaF may foster new approaches to developing treatments for vascular calcification.

16 January 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SPSanger Mouse Genetics Project
Sanger Mouse Genetics Project
GCGerry P Crossan
Gerry P Crossan
LWLouise van der Weyden
Louise van der Weyden
Iván Valle RosadoIván Valle Rosado
Iván Valle Rosado
FLFrederic Langevin
Frederic Langevin
KPKetan J Patel
Ketan J Patel
Ketan Patel and colleagues report a new mouse model of Fanconi anemia. The authors show that mice deficient in Btbd12, the mouse ortholog of SLX4 (a new Fanconi anemia gene), phenocopy the human disease. The evolutionarily conserved SLX4 protein, a key regulator of nucleases, is critical for DNA damage response. SLX4 nuclease complexes mediate repair during replication and can also resolve Holliday junctions formed during homologous recombination. Here we describe the phenotype of the Btbd12 knockout mouse, the mouse ortholog of SLX4, which recapitulates many key features of the human genetic illness Fanconi anemia. Btbd12-deficient animals are born at sub-Mendelian ratios, have greatly reduced fertility, are developmentally compromised and are prone to blood cytopenias. Btbd12−/− cells prematurely senesce, spontaneously accumulate damaged chromosomes and are particularly sensitive to DNA crosslinking agents. Genetic complementation reveals a crucial requirement for Btbd12 (also known as Slx4) to interact with the structure-specific endonuclease Xpf-Ercc1 to promote crosslink repair. The Btbd12 knockout mouse therefore establishes a disease model for Fanconi anemia and genetically links a regulator of nuclease incision complexes to the Fanconi anemia DNA crosslink repair pathway.

17 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
P. Stephen PatrickP. Stephen Patrick
P. Stephen Patrick
JHJayne Hammersley
Jayne Hammersley
LLLouiza Loizou
Louiza Loizou
MKMikko I. Kettunen
Mikko I. Kettunen
TRTiago B. Rodrigues
Tiago B. Rodrigues
KBKevin Brindle
Kevin Brindle
The ability to track cells and their patterns of gene expression in living organisms can increase our understanding of tissue development and disease. Gene reporters for bioluminescence, fluorescence, radionuclide, and magnetic resonance imaging (MRI) have been described but these suffer variously from limited depth penetration, spatial resolution, and sensitivity. We describe here a gene reporter, based on the organic anion transporting protein Oatp1a1, which mediates uptake of a clinically approved, Gd3+-based, hepatotrophic contrast agent (gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid). Cells expressing the reporter showed readily reversible, intense, and positive contrast (up to 7.8-fold signal enhancement) in T1-weighted magnetic resonance images acquired in vivo. The maximum signal enhancement obtained so far is more than double that produced by MRI gene reporters described previously. Exchanging the Gd3+ ion for the radionuclide, 111In, also allowed detection by single-photon emission computed tomography, thus combining the spatial resolution of MRI with the sensitivity of radionuclide imaging. Significance Gene reporters can be used to track viable cells in vivo and their patterns of gene expression. There have been numerous attempts to develop gene reporters for magnetic resonance imaging (MRI), however these give only modest image contrast and often this is negative, which can be difficult to detect. We describe here a dual-imaging modality reporter that gives intense and positive contrast in magnetic resonance images (up to ∼8× increase in signal), which can also be used with radionuclide imaging, thus combining the sensitivity of radionuclide imaging with the spatial resolution of MRI. The contrast obtained is directly related to the degree of gene expression and is readily reversible, thus allowing longitudinal studies of changes in expression.

4 April 2011 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ANAndré A. Neves
André A. Neves
HSHenning Stockmann
Henning Stockmann
RHRebecca R. Harmston
Rebecca R. Harmston
HPHelen J. Pryor
Helen J. Pryor
IAIsrat S. Alam
Israt S. Alam
KBKevin Brindle
Kevin Brindle
Cell surface glycans are involved in numerous physiological processes that involve cell‐cell interactions and migration, including lymphocyte trafficking and cancer metastasis. We have used a bioorthogonal metabolic labeling strategy to detect cell surface glycans and demonstrate, for the first time, fluorescence and radionuclide imaging of sialylated glycans in a murine tumor model in vivo. Peracetylated azido‐labeled N ‐acetyl‐man‐nosamine, injected intraperitoneally, was used as the metabolic precursor for the biosynthesis of 5‐azidoneuraminic, or azidosialic acid. Azidosialic acid‐labeled cell surface glycans were then reacted, by Staudinger ligation, with a biotinylated phosphine injected intraperitoneally, and the biotin was detected by subsequent intravenous injection of a fluorescent or radiolabeled avidin derivative. At 24 h after administration of NeutrAvidin, labeled with either a far‐red fluorophore or 111 In, there was a significant azido‐labeled N ‐acetyl‐mannosamine‐dependent increase in tumor‐to‐tissue contrast, which was detected using optical imaging or single‐photon‐emission computed tomography (SPECT), respectively. The technique has the potential to translate to the clinic, where, given the prognostic relevance of altered sialic acid expression in cancer, it could be used to monitor disease progression.—Neves, A. A., Stöckmann, H., Harmston, R. R., Pryor, H. J., Alam, I. S., Ireland‐Zecchini, H., Lewis, D. Y., Lyons, S. K., Leeper, F. J., Brindle, K. M. Imaging sialylated tumor cell glycans in vivo . FASEB J. 25, 2528–2537 (2011). www.fasebj.org

1 March 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
DSDmitry Soloviev
Dmitry Soloviev
DLDavid Lewis
David Lewis
DHDavina Honess
Davina Honess
EAEric Ofori Aboagye
Eric Ofori Aboagye

7 September 2015 in Gut
Verified
Journal Article
Open access
PDF file
ESEva M Serrao
Eva M Serrao
MKMikko I. Kettunen
Mikko I. Kettunen
TRTiago B Rodrigues
Tiago B Rodrigues
PDPiotr Dzien
Piotr Dzien
AWAlan J Wright
Alan J Wright
KBKevin Brindle
Kevin Brindle
Objectives: Pancreatic cancer (PCa) is treatable by surgery when detected at an early stage. Non-invasive imaging methods able to detect both established tumours and their precursor lesions are needed to select patients for surgery. We investigated here whether pancreatic preneoplasia could be detected prior to the development of invasive cancers in genetically engineered mouse models of PCa using metabolic imaging. Design: The concentrations of alanine and lactate and the activities of lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) were measured in extracts prepared from the pancreas of animals at different stages of disease progression; from pancreatitis, through tissue with predominantly low-grade and then high-grade pancreatic intraepithelial neoplasia and then tumour. 13 C magnetic resonance spectroscopic imaging ( 13 C-MRSI) was used to measure non-invasively changes in 13 C labelling of alanine and lactate with disease progression, following injection of hyperpolarised [1- 13 C]pyruvate. Results: Progressive decreases in the alanine/lactate concentration ratio and ALT/LDH activity ratio with disease progression were accompanied by a corresponding decrease in the [1- 13 C]alanine/[1- 13 C]lactate signal ratio observed in 13 C-MRSI images of the pancreas. Conclusions: Metabolic imaging with hyperpolarised [1- 13 C]pyruvate enables detection and monitoring of the progression of PCa precursor lesions. Translation of this MRI technique to the clinic has the potential to improve the management of patients at high risk of developing PCa.